Bank of America
SMMT icon

Bank of America’s Summit Therapeutics SMMT Stock Holding History

Bank of America’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6M Buy
864,983
+266,291
+44% +$4.72M ﹤0.01% 2874
2026
Q1 		$11.4M Buy
598,692
+121,299
+25% +$1.96M ﹤0.01% 2850
2025
Q4 		$8.35M Sell
477,393
-179,920
-27% -$3.38M ﹤0.01% 2989
2025
Q3 		$13.6M Buy
657,313
+91,166
+16% +$2.21M ﹤0.01% 2985
2025
Q2 		$12M Buy
566,147
+196,925
+53% +$4.49M ﹤0.01% 3060
2025
Q1 		$7.12M Sell
369,222
-62,346
-14% -$1.25M ﹤0.01% 3471
2024
Q4 		$7.7M Buy
431,568
+40,908
+10% +$793K ﹤0.01% 3197
2024
Q3 		$8.56M Buy
390,660
+49,513
+15% +$692K ﹤0.01% 3223
2024
Q2 		$2.66M Sell
341,147
-49,196
-13% -$266K ﹤0.01% 4199
2024
Q1 		$1.62M Buy
390,343
+268,051
+219% +$1.07M ﹤0.01% 4593
2023
Q4 		$319K Buy
122,292
+58,240
+91% +$120K ﹤0.01% 5794
2023
Q3 		$120K Buy
64,052
+54,476
+569% +$104K ﹤0.01% 6171
2023
Q2 		$24K Sell
9,576
-6,750
-41% -$12.3K ﹤0.01% 6670
2023
Q1 		$28.6K Buy
16,326
+7,374
+82% +$20.1K ﹤0.01% 6656
2022
Q4 		$38K Buy
8,952
+7,268
+432% +$13.2K ﹤0.01% 6566
2022
Q3 		$2K Buy
1,684
+1,478
+717% +$1.67K ﹤0.01% 7580
2022
Q2 		$0 Sell
206
-9,588
-98% -$13.4K ﹤0.01% 8346
2022
Q1 		$24K Sell
9,794
-9,517
-49% -$24K ﹤0.01% 7454
2021
Q4 		$52K Buy
19,311
+7,818
+68% +$37.6K ﹤0.01% 7202
2021
Q3 		$57K Buy
11,493
+2,803
+32% +$20.1K ﹤0.01% 6987
2021
Q2 		$65K Sell
8,690
-33,572
-79% -$220K ﹤0.01% 6713
2021
Q1 		$248K Buy
42,262
+31,872
+307% +$206K ﹤0.01% 5884
2020
Q4 		$49K Buy
10,390
+7,390
+246% +$31.3K ﹤0.01% 6335
2020
Q3 		$10K Hold
3,000
– – ﹤0.01% 6451
2020
Q2 		$9K Buy
+3,000
New +$10.3K ﹤0.01% 6471
2018
Q3 		– Sell
-100
Closed – – 7453
2018
Q2 		$0 Buy
100
+70
+233% +$896 ﹤0.01% 7298
2018
Q1 		$0 Buy
30
+25
+500% +$312 ﹤0.01% 7329
2017
Q4 		$0 Hold
5
– – ﹤0.01% 7229
2017
Q3 		$0 Buy
+5
New +$65 ﹤0.01% 7249

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bank of America's SMMT Position: Q2 2026 in Review

Bank of America increased its Summit Therapeutics (SMMT) stake by 44% in Q2 2026, buying an estimated $4.72M and bringing the position to 864,983 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2874.

Bank of America first reported a position in SMMT in Q3 2017 and has held it in 29 quarters since. The position peaked at $13.6M in Q3 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Bank of America held 864,983 shares of Summit Therapeutics worth $12.6M as of Q2 2026.
  • Bank of America bought 266,291 Summit Therapeutics shares in Q2 2026, an estimated $4.72M.
  • Summit Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #2874 holding.
  • Bank of America first reported a position in Summit Therapeutics in Q3 2017 and has held it in 29 quarters since.
  • Bank of America's Summit Therapeutics position peaked at $13.6M in Q3 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.